These studies not only elucidate an important mechanism of these immunomodulatory drugs but also provide evidence that small molecules hold the potential to repurpose E3 ubiquitin ligases for targeting “undruggable” targets, in particular GBM-relevant oncoproteins such as c-Myc, β-catenin or MCL1 (373). Here, MYC is linked to glioblastoma.